Rendu Bio

Shanghai Rendu Biotechnology Co., Ltd. is a high-tech enterprise with independent intellectual property rights in nucleic acid diagnostic technology, possessing a complete set of core technologies from sample processing to nucleic acid amplification detection and automated supporting instruments. The company integrates research and development, production, and market sales, focusing on the development and industrialization of novel nucleic acid detection technologies. Its products can be widely applied in clinical laboratory testing of pathogenic microorganisms, blood screening for infectious viruses, and environmental microorganism detection.

The company's independently developed Simultaneous Amplification and Testing (SAT) and Single Primer Amplification (SFA) systems organically combine isothermal nucleic acid amplification with real-time fluorescence detection, offering high sensitivity, strong specificity, low cross-contamination, and ease of full automation for high-throughput detection, representing the next generation of nucleic acid detection technology after PCR.

Based on the SAT technology platform, the company has completed the development and industrialization of diagnostic reagents for eugenics, enterovirus, respiratory, and food safety series. The GMP workshop passed national acceptance in 2008, and currently 10 products have obtained medical device registration certificates from the National Medical Products Administration and have entered the market (CT-SAT, NG-SAT, UU-SAT, TB-SAT, HFMD1-SAT, HFMD2-SAT, HFMD3-SAT, MP-SAT, MG-SAT, IAV-SAT). Food safety series products have also been launched. The fully automated supporting instrument for large-scale sample extraction, developed by the company itself, has begun market promotion and publicity.